Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Philips and BG Medicine form molecular medicine alliance
Under the partnership agreement, BG Medicine has granted Philips preferential access to certain of its proprietary technologies and services, and Philips has acquired a minority stake in BG
Under the partnership agreement, BG Medicine has granted Philips preferential access to certain of its proprietary technologies and services, and Philips has acquired a minority stake in BG
Bringing together respected scientists from related fields, the board will draw upon its members’ unique expertise to offer strategic counsel to the company. The board’s first priority is
The Tissue Repair Company’s (TRC) growth factor therapeutics have the potential to help heal tissue wounds such as dermal ulcers, which affect millions of diabetic patients. The assets
In preclinical studies, ATHX-105 has demonstrated a significant reduction of food intake and weight loss in established obesity models and a good safety profile across multiple animal species.
The strategic review, conducted by the board in conjunction with the company’s financial advisors and management, was initiated in January and included the evaluation of a number of
Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation that was developed using the company’s proprietary buccal drug delivery technologies. The product delivers glucose directly into the mouth where
Until now it was believed that Herceptin (trastuzumab) combined with cytotoxic drug therapy was effective only in HER-2-positive, or HER-2-overexpressing, breast cancer – which represents about 25% of
The conclusion was drawn after an interim analysis of 30 patients treated with a 4ml dose of AVR118, as well as an additional three patients treated with a
Positive trial results were achieved with a once-daily 775mg dose of Amoxicillin Pulsys for 10 days. The most commonly prescribed treatment for the management of group A streptococcal
Dacogen (decitabine) is a hypomethylating agent believed to exert its antineoplastic effects by incorporation into DNA and inhibition of an enzyme called DNA methyltransferase. Dacogen-induced hypomethylation in neoplastic